Autoimmunity's Hidden Language: Why the Immune System Sometimes Turns Against the Body

By Doanh Nguyen, MD FAAAAI, 06/03/2026

New discoveries are revealing that autoimmune diseases may begin long before symptoms appear, through a complex dialogue among genes, proteins, and the immune system itself.

The human immune system performs one of biology's most remarkable feats. Every day, it distinguishes friend from foe among trillions of cells, identifying invading viruses and bacteria while sparing the body's own tissues. Most of the time, it performs this task with extraordinary accuracy.

Yet for more than 800 million people worldwide living with autoimmune diseases, something goes wrong. The immune system begins attacking healthy organs, leading to conditions such as rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, and dozens of other disorders.

For decades, scientists viewed autoimmunity largely as a case of mistaken identity, a confused immune system attacking the wrong target. Today, however, advances in genetics and a rapidly evolving field known as immunopeptidomics are revealing a far more intricate story. Autoimmune disease may arise not simply because the immune system makes a mistake, but because the biological information it receives has been subtly altered.

The Body's Molecular Billboard

Every cell in the body constantly displays fragments of its internal proteins on specialized molecules called Human Leukocyte Antigens (HLAs). These molecules function much like tiny molecular billboards, presenting snippets of proteins to passing immune cells.

The immune system continuously scans these displays, searching for signs of infection or abnormality. If the displayed fragments appear dangerous, an immune response is triggered.

Scientists have known for decades that the genes encoding HLA molecules represent the strongest genetic risk factors for many autoimmune diseases. Certain HLA variants dramatically increase the likelihood of developing specific conditions, while others appear protective. What puzzled researchers was why.

The answer seems to lie in the types of protein fragments different HLA molecules choose to display. Each HLA variant has its own preferences, creating a unique portrait of the body's internal proteins. In effect, different people show their immune systems slightly different versions of themselves. Those differences can determine whether immune tolerance is maintained, or lost.

When the Volume Gets Turned Up

For years, researchers focused primarily on changes in the structure of HLA proteins themselves. More recently, however, scientists have uncovered an equally important factor: how much of these molecules are produced.

A study published in eLife revealed that many autoimmune risk variants do not alter proteins at all. Instead, they affect stretches of regulatory DNA that function like biological volume controls.These regulatory changes can increase the number of HLA molecules displayed on immune cells, making self-proteins more visible to the immune system.

In lupus, for example, certain genetic variants can substantially increase expression of HLA-DR and HLA-DQ molecules on dendritic cells, the immune system's professional sentinels. The result is analogous to increasing the brightness on a display screen. The immune system sees more information, more frequently, and potentially becomes more likely to react to proteins that would otherwise be ignored.

The discovery has transformed scientists' understanding of autoimmune risk. Sometimes the problem may not be that the immune system sees the wrong thing. It may simply be seeing too much.

Reading the Immune System's Secret Inventory

A second revolution is unfolding through the emerging science of immunopeptidomics. The term may sound esoteric, but the concept is straightforward. Using highly sensitive mass spectrometry, researchers can now catalog thousands of protein fragments presented by HLA molecules on living cells.For the first time, scientists can directly observe what the immune system is actually being shown.

This collection of displayed fragments, known as the immunopeptidome, acts as a molecular inventory of the body's proteins. Mapping it has revealed a surprising level of complexity. Rather than displaying a fixed set of protein fragments, cells generate a constantly changing collection of peptides shaped by genetics, cellular stress, inflammation, and environmental influences.

The immune system is therefore making decisions based on a dynamic stream of molecular information rather than a static snapshot.

The Mystery of New Self

One of the most important discoveries emerging from immunopeptidomics is that many autoimmune targets are not normal proteins at all.Instead, they are altered versions of ordinary proteins. Proteins frequently undergo chemical changes after they are produced. These modifications, known as post-translational modifications, help regulate cellular function. But they can also create entirely new structures that the immune system may not recognize.

Researchers estimate that roughly one in ten peptides displayed by HLA molecules contains such modifications.In rheumatoid arthritis, for example, a process called citrullination chemically alters proteins found throughout the body. These modified proteins can bind differently to disease-associated HLA molecules, creating new immune targets that may trigger chronic joint inflammation.In type 1 diabetes, scientists have identified an even stranger phenomenon. Cells can generate hybrid insulin peptides, formed by stitching together fragments from different proteins. These hybrid molecules do not exist in the normal genetic blueprint, yet they can become powerful targets for autoimmune T cells.

The findings suggest that autoimmunity may sometimes arise when the immune system encounters a version of "self" that it has never previously learned to tolerate.

A Different Disease, A Different Molecular Story

One of the most striking insights from recent research is that each autoimmune disease appears to possess its own molecular fingerprint.

In type 1 diabetes, immunopeptidomic studies have identified novel pancreatic autoantigens that may help explain why insulin-producing beta cells become selectively targeted.

In lupus, regulatory DNA variants appear to amplify antigen presentation and inflammatory signaling, potentially creating a self-reinforcing cycle of immune activation.

In rheumatoid arthritis, disease-associated HLA molecules display peptide repertoires that differ dramatically from those of protective variants. In some studies, the overlap between these peptide collections is surprisingly small, suggesting that different genetic backgrounds expose the immune system to fundamentally different molecular landscapes.

Rather than a single disease mechanism, autoimmunity increasingly appears to be a family of disorders united by a common outcome: the breakdown of immune tolerance.

Toward Precision Autoimmune Medicine

The implications extend far beyond understanding disease origins. Most current autoimmune treatments work by broadly suppressing immune activity. Although often effective, these therapies can leave patients vulnerable to infections and other complications because they dampen protective immune responses alongside harmful ones.

The long-term goal of immunopeptidomics is different.By identifying the precise molecules driving autoimmune reactions, researchers hope to develop therapies that retrain the immune system rather than suppress it. Instead of shutting down immunity, future treatments may teach immune cells to ignore specific disease-causing targets while preserving normal immune defenses.

Scientists are also exploring whether disease-specific peptide signatures could serve as early warning systems, identifying individuals at risk before symptoms emerge or before irreversible organ damage occurs.

Machine-learning algorithms are accelerating these efforts by helping predict which peptides are most likely to trigger immune responses, opening the possibility of highly personalized diagnostics and therapies.

The Future: From Immune Suppression to Immune Education

The emerging picture of autoimmunity is reshaping one of medicine's most challenging fields. What once appeared to be a simple case of immune confusion now looks more like a problem of biological communication. Genes influence which proteins are displayed. Regulatory DNA determines how loudly those signals are broadcast. Protein modifications create new molecular messages. And the immune system responds to the information it receives.

In this view, autoimmune diseases are not merely disorders of excessive immunity. They are disorders of immune information.

As researchers continue decoding the immunopeptidome, the hidden language spoken between cells and the immune system, they are moving closer to a future in which autoimmune diseases can be predicted earlier, diagnosed more precisely, and perhaps even prevented. For patients living with these conditions, that future cannot come soon enough.

Reference

1. Sønderstrup G, McDevitt HO. DR, DQ, and you: MHC alleles and autoimmunity. J Clin Invest. 2001;107(7):795-796. doi:10.1172/JCI12634

2. Raj P, Rai E, Song R, et al. Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity. Elife. 2016;5:e12089. Published 2016 Feb 15. doi:10.7554/eLife.12089

3. Arshad S, Cameron B, Joglekar AV. Immunopeptidomics for autoimmunity: unlocking the chamber of immune secrets. NPJ Syst Biol Appl. 2025;11(1):10. Published 2025 Jan 17. doi:10.1038/s41540-024-00482-x

4. Delong T, Wiles TA, Baker RL, et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. 2016;351(6274):711-714. doi:10.1126/science.aad2791

5. Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nat Rev Immunol. 2018;18(5):325-339. doi:10.1038/nri.2017.143